BBIO

BridgeBio Pharma, Inc.

9 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 13

Submission of NDA for Encaleret marks a transition to the regulatory approval phase.

regulatory action

70%

bearishMay 13

Concerns over thin cash runway and reliance on revolving credit lines.

dilution risk

40%

bullishMay 13

Submission of NDA for Encaleret marks a transition to the regulatory approval phase.

regulatory action

70%

bearishMay 13

Concerns over thin cash runway and reliance on revolving credit lines.

dilution risk

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

bearishMay 7

Company reported a net loss of $166.6 million for the quarter.

earnings miss

70%

bullishMay 7

Achieved approximately 96% gross margin on Attruby product sales.

margin expansion

90%

neutralMay 7

Issued $632.5 million in 2033 Convertible Senior Notes.

capital raise

60%

bullishMay 7

Repurchased common stock using proceeds from the 2033 Note offering.

buyback

40%

Filing History

8-KMay 13, 2026

The 8-K filing confirms that BridgeBio has officially entered the final regulatory stage for Encaleret, shifting the investment narrative from clinical trial results to regulatory approval probability. While the submission is a necessary step for commercial viability, the market must now weigh the potential for a successful launch against the risks of a thin balance sheet and the inherent uncertainty of FDA reviews for rare disease therapies. The outcome will likely be binary, depending on whether the FDA accepts the current data package or demands further pivotal studies.

10-QMay 7, 2026

The Q1 2026 filing reveals a company at a critical inflection point. BridgeBio has proven it can generate significant revenue and maintain elite margins, but it has not yet translated this into a sustainable bottom line. The core tension for investors lies in whether the rapid scaling of Attruby and the potential approval of BBP-418 can outpace the company's substantial debt service and operational burn. While the liquidity position is currently strong at $940 million, the structural reliance on convertible debt and royalty-backed financing means the margin for error is slim. The next 12 to 18 months will be decisive, as the market evaluates BridgeBio's ability to execute on its 'platform monetization' strategy and move toward a cash-flow positive state before its primary debt instruments reach critical conversion or maturity windows.